AstraZeneca vs Thermo Fisher Scientific

AstraZeneca (AZN), health care, and Thermo Fisher Scientific (TMO), health care, side by side on market value, valuation, margins, balance sheet and price change. Higher and lower are marked; neither is called better.

AstraZeneca is worth $283.9B on the stock market and Thermo Fisher Scientific $255.6B: AstraZeneca is valued at 11% more. AstraZeneca trades at 25.9 times earnings and Thermo Fisher Scientific at 36.4; operating margins in their latest fiscal years were 23.4% and 17.4%. Over the past year AstraZeneca's share price has moved +2.75% and Thermo Fisher Scientific's +20.0%.

Key facts

AstraZeneca market value
$283.9B
Thermo Fisher Scientific market value
$255.6B
AstraZeneca P/E
25.9
Thermo Fisher Scientific P/E
36.4
AstraZeneca revenue
$58.7BFY to 2025-12-31
Thermo Fisher Scientific revenue
$44.6BFY to 2025-12-31
Superinvestors holding both
7

Market values as of .

AstraZeneca vs Thermo Fisher Scientific: every measure side by side
Measure AstraZeneca Thermo Fisher Scientific
SectorHealth CareHealth Care
Country United Kingdom United States
Fiscal year ends2025-12-312025-12-31
Size
Market cap$283.9Bhigher$255.6Blower
Revenue$58.7Bhigher$44.6Blower
Earnings$10.2Bhigher$6.7Blower
Employees96,100lower125,000higher
Total assets$114.1Bhigher$110.3Blower
Valuation
P/E25.9lower36.4higher
P/S4.8lower5.7higher
P/B—4.7
Dividend yield—0.27%
Profitability
Operating margin23.4%higher17.4%lower
Balance sheet
Net assets$48.7Blower$53.4Bhigher
Total liabilities$65.4Bhigher$56.8Blower
Total debt$29.6Blower$39.4Bhigher
Cash on hand$5.7Blower$9.9Bhigher
Price change
Today-0.52%lower-0.23%higher
1 year+2.75%lower+20.0%higher

Market value, P/E, P/B, dividend yield and price changes are from live quotes (Yahoo Finance; prices may be delayed 15 minutes or more). Revenue, earnings, operating margin and the balance-sheet figures are from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day. P/S sets today's market value against the latest fiscal year's revenue. “Higher” and “lower” compare the two numbers only; a higher P/E or more debt is not better. Dividend yield and P/B are shown only for companies based in the US. A dash means no figure is on file.

Loading the one-year price chart…

Which superinvestors hold them

From each tracked investor's latest 13F filing. A 13F lists long positions in US-listed shares at a quarter end, filed up to 45 days later.

Percentages are each holding's share of that investor's reported portfolio (under "Both": AstraZeneca / Thermo Fisher Scientific). Who owns AZN · Who owns TMO

Further comparisons

Learn

Questions and answers

Which is bigger, AstraZeneca or Thermo Fisher Scientific?

By market value, AstraZeneca is the larger: $283.9B against $255.6B for Thermo Fisher Scientific. By revenue in its latest fiscal year, AstraZeneca is the larger: $58.7B against $44.6B for Thermo Fisher Scientific.

Which has the higher P/E ratio?

Thermo Fisher Scientific: 36.4, against 25.9 for AstraZeneca. A higher P/E means the market pays more for each dollar of the last twelve months' earnings; on its own it does not say which is the better value.

Which has the higher operating margin?

AstraZeneca: 23.4%, against 17.4% for Thermo Fisher Scientific. Operating margin is operating income as a share of revenue in the latest fiscal year.

Which has more debt?

Thermo Fisher Scientific: $39.4B, against $29.6B for AstraZeneca. Total debt is borrowings at the end of the latest fiscal year, as each company reported it; it is not set against cash here.

Which superinvestors own both AstraZeneca and Thermo Fisher Scientific?

In their latest 13F filings, Primecap team, Larry Robbins, Ken Fisher, Temasek, Andrew Spokes, Steve Cohen and Dodge & Cox team hold both.

Cite this page

Funkfolio, “AstraZeneca vs Thermo Fisher Scientific”, data as of 17 November 2026. https://funkfolio.com/compare/azn-vs-tmo

Underlying data: Yahoo Finance quotes; SEC annual reports collected 2026-11-12; 13F filings.